Literature DB >> 8397010

Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers.

Y C Horng1, M H Chang, C Y Lee, A Safary, F E Andre, D S Chen.   

Abstract

The immunogenicity and adverse reaction of an inactivated hepatitis A (HA) vaccine were investigated. Sixty healthy adult volunteers who lacked antibody to HA virus (anti-HAV) received three doses of vaccine containing 720 enzyme-linked immunosorbent assay (ELISA) units (EL.U) according to a 0, 1 and 6 month schedule. Blood tests for serum liver enzymes and anti-HAV were performed at screening 7 days prior to, and 1, 6 and 7 months after the first dose. Anti-HAV was tested by radio immunoassay and ELISA for titre determination. The seroconversion rates measured by ELISA were 98.3% (59/60) at months 1 and 6 and 100% at month 7. Sixty-one per cent (109/180) of the documented injections were followed by local symptoms, essentially mild soreness at the site of injection; and 22.2% (40/180) by minor general symptoms including malaise, fatigue and lethargy. It is concluded that HA vaccine is highly immunogenic and safe. It may replace immunoglobulin as an effective method of preventing HA virus infection in adults.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397010     DOI: 10.1111/j.1440-1746.1993.tb01524.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

1.  Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study.

Authors:  Jennifer C Nelson; Rachel C L Bittner; Lora Bounds; Shanshan Zhao; James Baggs; James G Donahue; Simon J Hambidge; Steven J Jacobsen; Nicola P Klein; Allison L Naleway; Kenneth M Zangwill; Lisa A Jackson
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

Review 2.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.